Loring Wolcott & Coolidge Fiduciary Advisors’s Quest Diagnostics DGX Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$149K	Buy	703 +655	+1,365%	+$129K	﹤0.01%	351
2026 Q1	$9.19K	Hold	48	–	–	﹤0.01%	522
2025 Q4	$8.84K	Hold	48	–	–	﹤0.01%	499
2025 Q3	$8.79K	Hold	48	–	–	﹤0.01%	505
2025 Q2	$8.62K	Hold	48	–	–	﹤0.01%	486
2025 Q1	$8.33K	Hold	48	–	–	﹤0.01%	492
2024 Q4	$7.68K	Hold	48	–	–	﹤0.01%	497
2024 Q3	$7.58K	Sell	48 -105	-69%	-$15.7K	﹤0.01%	507
2024 Q2	$22.7K	Sell	153 -182	-54%	-$24.9K	﹤0.01%	445
2024 Q1	$43.6K	Buy	335 +47	+16%	+$6.1K	﹤0.01%	407
2023 Q4	$37K	Hold	288	–	–	﹤0.01%	424
2023 Q3	$37.8K	Hold	288	–	–	﹤0.01%	441
2023 Q2	$40.5K	Buy	288 +48	+20%	+$6.62K	﹤0.01%	448
2023 Q1	$34K	Hold	240	–	–	﹤0.01%	441
2022 Q4	$37.5K	Hold	240	–	–	﹤0.01%	435
2022 Q3	$29K	Hold	240	–	–	﹤0.01%	467
2022 Q2	$32K	Hold	240	–	–	﹤0.01%	473
2022 Q1	$33K	Hold	240	–	–	﹤0.01%	477
2021 Q4	$42K	Hold	240	–	–	﹤0.01%	476
2021 Q3	$35K	Sell	240 -20	-8%	-$2.93K	﹤0.01%	486
2021 Q2	$34K	Buy	+260	New	+$34K	﹤0.01%	499
2021 Q1	–	Sell	-258	Closed	-$31K	–	404
2020 Q4	$31K	Sell	258 -1,482	-85%	-$181K	﹤0.01%	464
2020 Q3	$199K	Hold	1,740	–	–	﹤0.01%	260
2020 Q2	$198K	Sell	1,740 -120	-6%	-$12.7K	﹤0.01%	247
2020 Q1	$149K	Sell	1,860 -40	-2%	-$4.14K	﹤0.01%	257
2019 Q4	$203K	Hold	1,900	–	–	﹤0.01%	271
2019 Q3	$203K	Hold	1,900	–	–	﹤0.01%	267
2019 Q2	$193K	Buy	1,900 +400	+27%	+$38.4K	﹤0.01%	270
2019 Q1	$135K	Hold	1,500	–	–	﹤0.01%	293
2018 Q4	$125K	Hold	1,500	–	–	﹤0.01%	296
2018 Q3	$162K	Hold	1,500	–	–	﹤0.01%	284
2018 Q2	$165K	Hold	1,500	–	–	﹤0.01%	289
2018 Q1	$150K	Hold	1,500	–	–	﹤0.01%	307
2017 Q4	$148K	Hold	1,500	–	–	﹤0.01%	311
2017 Q3	$140K	Hold	1,500	–	–	﹤0.01%	317
2017 Q2	$162K	Hold	1,500	–	–	﹤0.01%	291
2017 Q1	$147K	Hold	1,500	–	–	﹤0.01%	304
2016 Q4	$138K	Hold	1,500	–	–	﹤0.01%	307
2016 Q3	$127K	Hold	1,500	–	–	﹤0.01%	312
2016 Q2	$122K	Hold	1,500	–	–	﹤0.01%	309
2016 Q1	$107K	Hold	1,500	–	–	﹤0.01%	311
2015 Q4	$107K	Hold	1,500	–	–	﹤0.01%	336
2015 Q3	$109K	Hold	1,500	–	–	﹤0.01%	347
2015 Q2	$109K	Hold	1,500	–	–	﹤0.01%	347
2015 Q1	$115K	Hold	1,500	–	–	﹤0.01%	353
2014 Q4	$101K	Hold	1,500	–	–	﹤0.01%	357
2014 Q3	$91K	Sell	1,500 -535	-26%	-$33K	﹤0.01%	351
2014 Q2	$119K	Hold	2,035	–	–	﹤0.01%	338
2014 Q1	$118K	Hold	2,035	–	–	﹤0.01%	318
2013 Q4	$109K	Hold	2,035	–	–	﹤0.01%	320
2013 Q3	$126K	Hold	2,035	–	–	﹤0.01%	288
2013 Q2	$123K	Buy	+2,035	New	+$121K	﹤0.01%	301

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

MGP

M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's DGX Position: Q2 2026 in Review

Loring Wolcott & Coolidge Fiduciary Advisors increased its Quest Diagnostics (DGX) stake by 1,365% in Q2 2026, buying an estimated $129K and bringing the position to 703 shares worth $149K. The position accounts for ﹤0.01% of the portfolio, ranked #351.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in DGX in Q2 2013 and has held it in 52 quarters since. The position peaked at $203K in Q4 2019. 629 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Loring Wolcott & Coolidge Fiduciary Advisors held 703 shares of Quest Diagnostics worth $149K as of Q2 2026.
Loring Wolcott & Coolidge Fiduciary Advisors bought 655 Quest Diagnostics shares in Q2 2026, an estimated $129K.
Quest Diagnostics made up ﹤0.01% of Loring Wolcott & Coolidge Fiduciary Advisors's portfolio in Q2 2026, its #351 holding.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Quest Diagnostics in Q2 2013 and has held it in 52 quarters since.
Loring Wolcott & Coolidge Fiduciary Advisors's Quest Diagnostics position peaked at $203K in Q4 2019.
629 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.